Hypofractionated radiotherapy for nasopharyngeal carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the efficacy and safety of hypofractionated radiotherapy in patients with nasopharyngeal carcinoma (NPC), comparing it to conventional radiotherapy methods. NPC is a prevalent head and neck cancer, particularly in southern China, where radiotherapy is the primary treatment. The study aims to determine if hypofractionated radiotherapy can improve local control of tumor cells while minimizing damage to surrounding organs and reducing treatment duration. By addressing the accelerated reproliferation of tumor cells, the study seeks to enhance patient outcomes and quality of life.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18-75 years, male or female；
2. Performance status ≤ 2 ;
3. Nasopharyngeal cancer patients diagnosed by pathology (including histology or cytology) , of nasopharyngeal non-keratonic carcinoma (differentiated or undifferentiated, whether TNM staging);
4. Have at least one evaluable lesion (according to Recist1.1 criteria)
5. Expected survival ≥6 months.
6. The main organs are functioning normally and meet the following standards: (1) Blood routine examination must meet the following criteria: (no blood transfusion within 14 days) a. HB ≥ 100g/L, b. WBC ≥3×10\^9/L c. ANC≥1.5×10\^9/L, d. PLT ≥100×10\^9/L; (2) Biochemical examination must meet the following standards: a. BIL\<1.5 times the upper limit of normal value (ULN), b. ALT and AST\<2.5ULN, GPT ≤1.5×ULN; c. Serum Cr≤1 ULN, endogenous creatinine clearance rate\>60ml/min (Cockcroft Gault formula);(3).Good coagulation function: defined as International standardized ratio (INR) or prothrombin time (PT) ≤1.5×ULN;(4).The myocardial enzyme spectra were in the normal range.
7. Patients willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the Clinical Investigation Plan tests and procedures.

Exclusion Criteria:

1. Pregnant or lactating women
2. As determined by the investigators, there were severe comorbidities that could not tolerate or complete radiation therapy.
3. There are contraindications in MRI;
4. Second primary malignancy exists;
5. Patients with severe complications,such as hypertension, coronary heart disease,mental disease or patients who had any allergies before;
6. Received any other research in the past 4 weeks before enrollment.

Where it's running

• The Second Affiliated Hospital of Hainan Medical University
  Haikou, Hainan, China Recruiting

Study contacts

• Study coordinator: yuecan zeng, doctor
• Email: wellyy2005@hainmc.edu.cn
• Phone: 19946610752

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Structured swallowing exercises for nasopharyngeal cancer patients

  This trial tests whether a structured swallowing exercise program improves swallowing and quality of life more than conventional swallowing exercises in adults with nasopharyngeal carcinoma.

  Recruiting Universitas Indonesia · Jakarta Pusat, DKI Jakarta · NCT07909538

• Dynamic risk prediction for severe blood cell suppression in nasopharyngeal cancer

  This study tests a dynamic risk model to see if it can predict grade 3 or higher anemia, low platelets, or low white blood cells during systemic therapy for adults with nasopharyngeal cancer.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07819656

• Becotatug Vedotin plus PD-1 inhibitor for locally recurrent nasopharyngeal carcinoma

  This study tests whether adding becotatug vedotin to a PD-1 inhibitor helps people with locally recurrent nasopharyngeal cancer.

  Recruiting Phase 2 Eye & ENT Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT07781358

• Dynamic risk-guided EBV-DNA and MRI-based chemotherapy adjustments in nasopharyngeal carcinoma

  This trial tests whether adjusting adjuvant therapy based on changes in EBV DNA and MRI findings after radiotherapy helps improve outcomes for people with nasopharyngeal carcinoma.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07762976

• Immune Sandwich: Induction with Nimotuzumab and Toripalimab Plus Radiotherapy vs Full-Course Immunotherapy for Advanced Nasopharyngeal Cancer

  This trial tests whether a shortened, targeted immunotherapy plan added to chemoradiation can match the full immunotherapy approach for locally advanced nasopharyngeal cancer in adults 18–70.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07706985

• RAIRI-guided risk-stratified adjuvant therapy after chemoradiotherapy in nasopharyngeal carcinoma

  This real-world study tests whether the RAIRI model can predict who will benefit from adjuvant therapy after chemoradiotherapy for non-metastatic nasopharyngeal carcinoma.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07618078

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.